Melanie B Thomas

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. ncbi request reprint Curing hepatocellular carcinomatosis with biologic therapy and surgery: achieving the impossible?
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Surg Oncol 97:82-4. 2008
  2. doi request reprint Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, Texas 77030 4009, USA
    Ann Surg Oncol 15:1008-14. 2008
  3. doi request reprint Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:843-50. 2009
  4. pmc Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting
    Melanie B Thomas
    Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Clin Oncol 28:3994-4005. 2010
  5. doi request reprint Systemic and targeted therapy for biliary tract tumors and primary liver tumors
    Melanie Byrne Thomas
    Hollings Cancer Center, College of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA Electronic address
    Surg Oncol Clin N Am 23:369-81. 2014
  6. pmc The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Hepatol 50:334-41. 2009
  7. pmc Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hepatology 49:1563-70. 2009
  8. ncbi request reprint A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors
    Benjamin Friday
    College of Medicine, Medical University of South Carolina, Charleston, 20 Cape Flattery Ct, Irmo, SC 29063, USA
    Anticancer Res 32:1689-96. 2012
  9. doi request reprint Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
  10. doi request reprint Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies
    Lisa A Hammond-Thelin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Invest New Drugs 30:316-26. 2012

Detail Information

Publications25

  1. ncbi request reprint Curing hepatocellular carcinomatosis with biologic therapy and surgery: achieving the impossible?
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Surg Oncol 97:82-4. 2008
    ..She received biologically targeted systemic therapy which resulted in significant radiographic tumor response. Salvage surgery revealed complete pathologic response in all tumor nodules, thus the patient was rendered cancer-free...
  2. doi request reprint Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, Texas 77030 4009, USA
    Ann Surg Oncol 15:1008-14. 2008
    ..This review summarizes the results of prospective clinical trials of several categories of systemic therapy, with emphasis on the more promising results from recent trials of biologically targeted therapeutic agents in HCC...
  3. doi request reprint Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:843-50. 2009
    ..Secondary objectives included response rate, median PFS, survival, and toxicity...
  4. pmc Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting
    Melanie B Thomas
    Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Clin Oncol 28:3994-4005. 2010
    ..The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need...
  5. doi request reprint Systemic and targeted therapy for biliary tract tumors and primary liver tumors
    Melanie Byrne Thomas
    Hollings Cancer Center, College of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA Electronic address
    Surg Oncol Clin N Am 23:369-81. 2014
    ..The HCC community needs validated biomarkers to help identify the patients who will benefit most from emerging treatment options. ..
  6. pmc The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Hepatol 50:334-41. 2009
    ..The study aimed at addressing the connection between positive family history of liver cancer and hepatocellular carcinoma (HCC) development in the USA...
  7. pmc Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hepatology 49:1563-70. 2009
    ..Experimental investigations are necessary for thorough assessment of the relationship between thyroid disorders and HCC...
  8. ncbi request reprint A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors
    Benjamin Friday
    College of Medicine, Medical University of South Carolina, Charleston, 20 Cape Flattery Ct, Irmo, SC 29063, USA
    Anticancer Res 32:1689-96. 2012
    ..This phase I study was conducted in order to determine the recommended phase II dose of TAS-106 administered once per week for three consecutive weeks, every 28 days in patients with solid tumors...
  9. doi request reprint Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
    ....
  10. doi request reprint Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies
    Lisa A Hammond-Thelin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Invest New Drugs 30:316-26. 2012
    ..This study was performed to principally evaluate the feasibility of administering TAS-106 as a bolus intravenous (IV) infusion every 3 weeks...
  11. ncbi request reprint Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 110:1059-67. 2007
    ..The primary objective of this study was to determine the proportion of hepatocellular carcinoma (HCC) patients treated with erlotinib who were alive and progression-free (PFS) at 16 weeks of continuous treatment...
  12. doi request reprint A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
    Kimberly B Higginbotham
    Department of Gastrointestinal Medical Oncology Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Cancer Res Clin Oncol 134:1325-35. 2008
    ..Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts)...
  13. ncbi request reprint Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
    ..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
  14. doi request reprint Systemic therapy for hepatocellular carcinoma
    Melanie B Thomas
    Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:123-7. 2008
    ..Newer biologic agents that target molecular abnormalities common to HCC may improve the clinical outcome in patients with HCC...
  15. pmc Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 123:1883-91. 2008
    ..Controlling for smoking exposure might be a prudent approach to the prevention of HCC, especially in patients with chronic viral hepatitis infections...
  16. doi request reprint Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Invest New Drugs 26:445-54. 2008
    ..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules...
  17. pmc Prognostic factors in relation to racial disparity in advanced colorectal cancer survival
    Kristin Wallace
    Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC Hollings Cancer Center, Medical University of South Carolina, Charleston, SC Electronic address
    Clin Colorectal Cancer 12:287-93. 2013
    ..Colorectal cancer mortality rates are significantly greater in AA than in EA individuals, and the disparity is worsening. We investigated the relationship between race and metastatic CRC (mCRC) survival in younger and older patients...
  18. ncbi request reprint Hepatocellular carcinoma: the need for progress
    Melanie B Thomas
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2892-9. 2005
  19. ncbi request reprint Opportunities for targeted therapies in hepatocellular carcinoma
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:8093-108. 2005
    ..Relevant preclinical and clinical information on novel compounds directed toward abnormalities in HCC is reviewed...
  20. ncbi request reprint Liver resection in the treatment of hepatocellular carcinoma
    Dario Ribero
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:567-79. 2006
    ..An overview of the most common staging systems, which are useful in predicting prognosis after liver resection for hepatocellular carcinoma, is given...
  21. doi request reprint Targeted therapies for cancer of the gallbladder
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Curr Opin Gastroenterol 24:372-6. 2008
    ..Adenocarcinomas of the gallbladder are uncommon, aggressive tumors with poor survival. This review summarizes advances in understanding the biology of gallbladder cancer...
  22. pmc Racial disparities in advanced-stage colorectal cancer survival
    Kristin Wallace
    Division of Epidemiology and Biostatistics, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
    Cancer Causes Control 24:463-71. 2013
    ..In the present study, statewide, population-based data from South Carolina Central Cancer Registry are used to investigate the relationship between race and age on advanced-stage CRC survival...
  23. ncbi request reprint Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy
    Melanie B Thomas
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 61:44-51. 2007
    ..Improved understanding of the biological characteristics and molecular carcinogenic mechanisms of these malignancies may lead to improved therapeutic regimens for patients...
  24. pmc HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer
    Toru Kawamoto
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX
    Gastrointest Cancer Res 1:221-7. 2007
    ..Tumor specimens from patients from the United States and Chile were examined for expression of HER-2/neu, EGFR, and their activated forms (p-erbB2, p-EGFR)...
  25. ncbi request reprint Advances in the surgical management of liver malignancies
    Timothy M Pawlik
    The University of Texas M D Anderson Cancer Center, Department of Surgical Oncology, Houston, Texas 77030, USA
    Cancer J 10:74-87. 2004
    ..Two recent randomized studies have also indicated improved survival after hepatic artery embolization in selected patients...